Joelle Baddour

Joelle Baddour has been working in the scientific and engineering fields since 2007. Joelle began their career as an Undergraduate Researcher and Engineering Workshop Manager at the University of Dayton. In 2010, they became a Graduate Research Assistant at the same university, where they studied cataract eye disease in mice and newts. In 2012, they moved to Rice University as a Graduate Research and Teaching Assistant, where they developed and patented a combinatorial treatment that successfully recapitulated the quiescent profile of pancreatic, ovarian and prostate stromal cells at the genetic, metabolic and phenotypic levels. In 2015, they interned at Baylor College of Medicine as a Graduate Research Intern, where they developed a procedure for of 13C and 15N stable isotope tracing using gas chromatography-mass spectrometry. In 2017, Joelle joined XTuit Pharmaceuticals, Inc. as a Research Scientist, Biomarker Development, where they identified, validated and nominated a drug response-predictive set of pharmacokinetic-pharmacodynamic (PK/PD) biomarkers in oncology and chronic inflammatory/fibrotic diseases. Joelle also developed and optimized an innovative multiplex biomarker diagnostic platform assay. In 2018, they moved to C4 Therapeutics, Inc. as a Research Scientist II, In Vivo Pharmacology and Research Scientist I, Translational Biology. Most recently, in 2021, Joelle joined ROME Therapeutics as a Senior Scientist.

Joelle Baddour received their Bachelor of Science in Chemical Engineering from the University of Dayton in 2010. Joelle then continued their studies at the same institution, earning a Master of Science in Bioengineering in 2012. In 2016, they completed their Doctor of Philosophy in Chemical and Biomolecular Engineering at Rice University.